Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib plus Trastuzumab Maintenance in HER2+ MBC
NCT00968968Phase 3Terminated
- Sponsor
- Novartis
- Start
- Jan 2010
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of lapatinib in HER2-positive metastatic breast cancer (2 arms), sponsored by Novartis. Primary endpoint: Progression-free Survival at 4 years. Started Jan 2010; status: terminated.
02
Drugs
lapatinib
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT00968968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00968968.